- Shares of recently public Relypsa (RLYP +7.2%) are up sharply in morning trading.
- Wedbush is initiating at Outperform, citing Patiromer potential.
- The hyperkalemia treatment "has shown a potentially best-in-class profile [and] can achieve peak annual sales of about $1.4B in the U.S," analyst Liana Moussatos says.
- Price target is $34, representing upside of 70% from Monday's close.
Wedbush sees big upside for Relypsa
Dec 10 2013, 10:07 ET